// App-Quantinova.ai

THU0300 (2018) : Network meta-analysis of tofacitinib vs bdmards or apremilast for the treatment of tnf inhibitor-naÏve patients with psoriatic arthritis

Researchers

Presenter

  • D.D. Gladman

Principal Investigators

  • A.-M. Orbai

  • J. Gomez-Reino

  • S. Chang-Douglass

  • E. Leoncini

  • H.E. Burton

  • K.S. Kanik

  • T. Hendrikx

  • J.C. Cappelleri

  • M.-A. Hsu

Medical Centers

  • Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Hospital Clinico Universitario, Santiago De Compostela, Spain

  • Decision Resources Group, London, UK

  • Pfizer, Groton, CT

  • Pfizer Inc, Collegeville, PA

Locations

  • Canada

  • United States

  • Spain

  • United Kingdom

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Tasocitinib

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved